RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance.
• Group now sees lower than expected Q3 2024 and FY 2024 SUBLOCADE net revenue (NR) from a combination of faster initial adoption among treatment providers of the competing long-acting injectable (LAI), variability in the timing of funding among certain Criminal Justice System (CJS) accounts and incremental lower trade stocking.
◦ Preliminary Q3 2024 SUBLOCADE NR: $187m to $192m
◦ Revised FY 2024 SUBLOCADE NR: $725m to $745m (+17% at the midpoint vs. FY 2023)
• Expected peak SUBLOCADE NR of >$1.5 billion is unchanged, however the Group no longer expects a SUBLOCADE NR run rate of $1 billion exiting 2025.
• The Group is actively seeking efficiencies to fuel SUBLOCADE growth and support margins.